Procyrion Inc. Earns €30,000 for Circulatory Support Pump in International Life Sciences Competition
Houston, TX, October 08, 2015 --(PR.com)-- Houston heart pump developer Procyrion Inc. (http://www.procyrion.com) earned the 2015 Universal Biotech Innovation Prize for Aortix™, a catheter-based circulatory support device. With the top two most innovative projects, Procyrion and Pixium Vision, will share a grant award and a year of consulting services offered by organizer Universal Biotech, valued at €60,000. Procyrion CEO Benjamin A. Hertzog, Ph.D. and senior product development engineer Omar Benavides, Ph.D., traveled to Paris, France to accept the Innovation Prize, now in its seventh year.
With its catheter-deployed heart pump Aortix™, Procyrion aims to give NYHA Class III-IVa heart failure patients a better quality-of-life by allowing the heart to rest and heal while increasing blood flow to vital organs. The small but powerful micro-pump is placed downstream of the heart in a simple cath-lab procedure and works to support heart function by accelerating native blood flow in the aorta. Designed specifically to reduce the risks associated with existing technologies (e.g. stroke, infection, and catastrophic device failure), Aortix is thinner than a No. 2 pencil, yet was still able to reduce the workload of the heart by almost 40% in pre-clinical studies.
“We’re working to change the outlook for millions around the world who suffer from chronic heart failure. This international recognition among other ground-breaking innovations underscores the need for improved cardiovascular therapies,” said Benavides.
Adds Hertzog, ”As an entrepreneur, the validation is invaluable to our entire team in reminding us that we’re on the right track and are a part of something with the potential to help so many patients suffering from chronic heart failure.”
Developed by renowned Texas Heart Institute cardiologist Dr. Reynolds Delgado III, Aortix was selected from a pool of more than 280 applicants and evaluated by a jury of international experts in life sciences based on scientific quality, level of IP, project feasibility, chance of market success, and quality of the company’s human resources.
Just last week, Procyrion earned the $20,000 grand prize in another innovation design competition.
Launched in 2009 and based in France, the Innovation Prize is organized by Universal Biotech, a division of Universal Medica Group.
Procyrion’s Aortix is not approved for use or sale.
About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit www.procyrion.com or call 713.579.9227.
With its catheter-deployed heart pump Aortix™, Procyrion aims to give NYHA Class III-IVa heart failure patients a better quality-of-life by allowing the heart to rest and heal while increasing blood flow to vital organs. The small but powerful micro-pump is placed downstream of the heart in a simple cath-lab procedure and works to support heart function by accelerating native blood flow in the aorta. Designed specifically to reduce the risks associated with existing technologies (e.g. stroke, infection, and catastrophic device failure), Aortix is thinner than a No. 2 pencil, yet was still able to reduce the workload of the heart by almost 40% in pre-clinical studies.
“We’re working to change the outlook for millions around the world who suffer from chronic heart failure. This international recognition among other ground-breaking innovations underscores the need for improved cardiovascular therapies,” said Benavides.
Adds Hertzog, ”As an entrepreneur, the validation is invaluable to our entire team in reminding us that we’re on the right track and are a part of something with the potential to help so many patients suffering from chronic heart failure.”
Developed by renowned Texas Heart Institute cardiologist Dr. Reynolds Delgado III, Aortix was selected from a pool of more than 280 applicants and evaluated by a jury of international experts in life sciences based on scientific quality, level of IP, project feasibility, chance of market success, and quality of the company’s human resources.
Just last week, Procyrion earned the $20,000 grand prize in another innovation design competition.
Launched in 2009 and based in France, the Innovation Prize is organized by Universal Biotech, a division of Universal Medica Group.
Procyrion’s Aortix is not approved for use or sale.
About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit www.procyrion.com or call 713.579.9227.
Contact
Procyrion Inc
Anna Halvorson
713.510.0500
www.procyrion.com
Anna Halvorson
713.510.0500
www.procyrion.com
Contact
Categories